SCHEMBL6664260

SCHEMBL6664260

C[CH]c1c[nH]nc1C(N)=O

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.30
CDK8 P49336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30902000 0.85 PDPK1 (0.32)
SCHEMBL29952738 0.82 ERN1 (0.32)
SCHEMBL169065 0.74
SCHEMBL13735546 0.73 IDO1 (0.33) CCNCCDK8
SCHEMBL956225 0.71
SCHEMBL9799881 0.71 ALDH1A1 (0.34)
SCHEMBL9081285 0.71 IKBKB (0.39)
SCHEMBL27744212 0.71 JAK2 (0.37) CCNCCDK8
SCHEMBL12655180 0.69
SCHEMBL2591837 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP claimed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO claimed